NCT06146985 2023-11-28
Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer
Ruijin Hospital
Phase 2 Unknown
Clinical Trials
16 trialsNCT05182931 2023-10-31
I-FIRST
Olivia Newton-John Cancer Research Institute
Phase 2 Unknown
NCT04619316 2023-06-22
ERRITI
University Hospital, Essen
Phase 2 Unknown
NCT05659186 2022-12-21
PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer
West China Hospital
Phase 2 Unknown
NCT05299437 2022-03-29
131THEROPT124
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT04952493 2022-01-28
Anlotinib or Penpulimab in Combination With RAI for DTC
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04309136 2021-04-01
Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
Fudan University
Phase 2 Unknown
NCT04554680 2021-03-05
Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy
National University Hospital, Singapore
Phase 2 Unknown
NCT04612894 2020-11-03
Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer
Fudan University
Phase 2 Unknown
NCT04524884 2020-08-24
Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study
Fudan University
Phase 2 Unknown
NCT03300765 2017-10-03
Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer
Fudan University
Phase 2 Unknown
NCT01830504 2016-10-05
BKM120
Hospices Civils de Lyon
Phase 2 Unknown
NCT00098852 2014-01-06
Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01118065 2013-08-12
Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00786552 2011-01-20
Panthera
University Hospital Schleswig-Holstein
Phase 2 Unknown
NCT00948337 2010-02-26
A Study With Health Educational Material on Health Promotion in Cancer Survivors
National Cancer Center, Korea
Phase 2 Unknown